HeartFlow
HeartFlow's revenue rose 39.9% to $176 million in fiscal 2025. Its operating margin was −36.4%, up from −48.7% a year earlier. Free cash flow was −$59 million. The diluted share count rose 587.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
What HeartFlow does
Heartflow sells software and artificial intelligence (AI) that help doctors diagnose and manage coronary artery disease (CAD), in which plaque builds up in the heart's arteries and restricts blood flow. Its platform takes a heart scan known as a coronary CT angiogram and builds a personalized 3D model of the patient's heart. From the model, it shows how blood flows, how narrow the arteries are, and how much plaque there is and what it is made of.
Heartflow says its platform has been used to assess CAD in more than 600,000 patients. Its revenue comes almost entirely from one product, Heartflow FFR CT Analysis. A newer product, Heartflow Plaque Analysis, is still at an early stage of sale.
The company competes with traditional tests for CAD, such as stress tests, and says its approach is more accurate. Its sales depend on hospitals and other providers changing how they evaluate CAD and on insurers paying for the analysis. It has a concentrated customer base.
Its biggest risks, as it describes them
- Almost all its revenue comes from one product, Heartflow FFR CT Analysis.
- Healthcare providers may be unwilling to change how they evaluate coronary artery disease.
- Insurers and government payors may not cover or pay enough for the platform.
- It has a concentrated customer base and has lost money since it began.
- Its AI models may have errors or create legal and reputational problems.
Income statement
HeartFlow lost money in fiscal 2025: a net loss of $117 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 123 | 51 | 280 |
| Debt incl. finance leases | — | — | — |
| Net debt (negative means net cash) | — | — | — |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | — | — |
| Interest coverage | −3.0x | −2.7x | −4.2x |
| Current ratio | — | 2.5x | 5.2x |
| Quick ratio | — | 2.5x | 5.2x |
Cash flow
Projections
Project HeartFlow's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What HeartFlow says to expect
- Full year 2026: total revenue
Total revenue of $262 million to $264 million (approximately 49% to 50% growth year-over-year), compared to previous guidance of $246 million to $250 million (approximately 40% to 42% growth year-over-year)
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $1.1 million of HeartFlow shares on the open market, and 6 insiders sold $138.1 million, $23.1 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 18, 2026 | Campbell RogersChief Medical Officer | Sold plan | 19,682 | $50.15 | $987,052 | Form 4 |
| Sep 18, 2026 | Vikram VergheseChief Financial Officer | Sold plan | 16,766 | $50.75 | $850,874 | Form 4 |
| Sep 17, 2026 | Vikram VergheseChief Financial Officer | Sold plan | 7,579 | $50.11 | $379,784 | Form 4 |
| Sep 15, 2026 | Vikram VergheseChief Financial Officer | Sold plan | 668 | $50.01 | $33,407 | Form 4 |
| Sep 14, 2026 | Vikram VergheseChief Financial Officer | Sold plan | 4,593 | $50.24 | $230,752 | Form 4 |
| Sep 11, 2026 | Vikram VergheseChief Financial Officer | Sold plan | 29,714 | $50.06 | $1.5 million | Form 4 |
| Sep 11, 2026 | John C.M. FarquharChief Executive Officer, Director | Sold plan | 3,890 | $50.00 | $194,500 | Form 4 |
| Sep 10, 2026 | John C.M. FarquharChief Executive Officer, Director | Sold plan | 35,010 | $46.42 | $1.6 million | Form 4 |
| Sep 8, 2026 | Vikram VergheseChief Financial Officer | Sold plan | 6,640 | $50.03 | $332,199 | Form 4 |
| Sep 3, 2026 | Vikram VergheseChief Financial Officer | Sold plan | 27,540 | $49.69 | $1.4 million | Form 4 |
| Sep 2, 2026 | Vikram VergheseChief Financial Officer | Sold plan | 5,876 | $50.60 | $297,326 | Form 4 |
| Aug 21, 2026 | John C.M. FarquharChief Executive Officer, Director | Sold plan | 27,230 | $50.00 | $1.4 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | −14.0% | 6.4% |
| Altman Z'' | −31.75 | −2.45 |
| Accruals ratio | — | −26.2% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | — | Fail |
| Cash from operations is positive | Fail | Fail |
| Return on assets rose | — | — |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | Pass |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | Pass | Pass |
| Revenue rose relative to assets | — | — |
| F-score | — | — |
Compare
Put HeartFlow side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| HeartFlow | FY25 | 39.9% | −36.4% | −33.5% | — | — | — | |
| Omada Health | FY25 | 53.2% | −4.6% | 6.5% | — | — | — | Compare |
| HealthStream | FY25 | 4.3% | 6.7% | 19.6% | — | — | — | Compare |
| Certara | FY25 | 8.8% | 5.0% | 22.6% | 0.9% | 1.1x | 5 | Compare |
| Phreesia | FY26 | 14.5% | −1.4% | 14.1% | −2.2% | −2.6x | 6 | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 87 | 126 | 176 |
| Revenue growth | — | 44.3% | 39.9% |
| Gross profit | 58 | 94 | 135 |
| Research and development | 36 | 44 | 65 |
| Operating income | −73 | −61 | −64 |
| Net income | −96 | −96 | −117 |
| Diluted EPS (US$) | −25.32 | −17.98 | −3.17 |
| Diluted shares (millions) | 5 | 5 | 37 |
| Cash flow | |||
| Cash from operations | −76 | −69 | −54 |
| Capital expenditure | 6 | 4 | 5 |
| Free cash flow | −83 | −73 | −59 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 12 | 10 | 14 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 123 | 51 | 280 |
| Debt incl. finance leases | — | — | — |
| Total assets | — | 119 | 360 |
| Total liabilities | — | 210 | 59 |
| Shareholders' equity | −778 | −860 | 301 |
| Margins and ratios | |||
| Gross margin | 66.6% | 75.1% | 76.8% |
| Operating margin | −83.6% | −48.7% | −36.4% |
| Net margin | −109.7% | −76.7% | −66.3% |
| Free cash flow margin | −94.7% | −58.3% | −33.5% |
| Rule of 40 (growth + FCF margin) | — | −14.0% | 6.4% |
| Return on capital | — | — | — |
| Return on equity | — | — | — |
| Return on assets | — | — | −48.9% |
| Net debt to EBITDA | — | — | — |